Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Faes Farma stock

FAE.MC
ES0134950F36
A0MKAC

Price

3.69
Today +/-
+0.02
Today %
+0.54 %
P

Faes Farma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Faes Farma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Faes Farma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Faes Farma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Faes Farma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Faes Farma Stock Price History

DateFaes Farma Price
10/4/20243.69 undefined
10/3/20243.67 undefined
10/2/20243.69 undefined
10/1/20243.72 undefined
9/30/20243.72 undefined
9/27/20243.72 undefined
9/26/20243.68 undefined
9/25/20243.65 undefined
9/24/20243.65 undefined
9/23/20243.67 undefined
9/20/20243.71 undefined
9/19/20243.75 undefined
9/18/20243.72 undefined
9/17/20243.67 undefined
9/16/20243.74 undefined
9/13/20243.71 undefined
9/12/20243.68 undefined
9/11/20243.69 undefined
9/10/20243.68 undefined
9/9/20243.70 undefined
9/6/20243.67 undefined

Faes Farma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Faes Farma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Faes Farma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Faes Farma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Faes Farma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Faes Farma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Faes Farma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Faes Farma’s growth potential.

Faes Farma Revenue, EBIT and net profit per share

DateFaes Farma RevenueFaes Farma EBITFaes Farma Net Income
2027e515.45 M undefined96.58 M undefined88.59 M undefined
2026e513.57 M undefined110.13 M undefined92.21 M undefined
2025e499.02 M undefined108.59 M undefined93.52 M undefined
2024e484.62 M undefined105.21 M undefined90.38 M undefined
2023451.17 M undefined102.84 M undefined91.9 M undefined
2022438.75 M undefined101.92 M undefined89.55 M undefined
2021398.56 M undefined97.11 M undefined82.39 M undefined
2020380.24 M undefined92.31 M undefined72.55 M undefined
2019357.4 M undefined78.98 M undefined63.96 M undefined
2018324.31 M undefined62.01 M undefined51.59 M undefined
2017274.58 M undefined49.07 M undefined41.38 M undefined
2016228.64 M undefined48.04 M undefined36.59 M undefined
2015204.72 M undefined41.52 M undefined30.36 M undefined
2014191.7 M undefined36.2 M undefined25.3 M undefined
2013180.4 M undefined28.6 M undefined22.6 M undefined
2012176.1 M undefined22.8 M undefined19.5 M undefined
2011195.7 M undefined16.3 M undefined14.2 M undefined
2010211.4 M undefined24.7 M undefined20 M undefined
2009199.4 M undefined25.4 M undefined21.3 M undefined
2008196.9 M undefined26 M undefined19.6 M undefined
2007203.9 M undefined21.4 M undefined21.9 M undefined
2006192.5 M undefined23.3 M undefined22.8 M undefined
2005168.7 M undefined19.9 M undefined23.3 M undefined
2004165.1 M undefined15.1 M undefined20.6 M undefined

Faes Farma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
94103110121134149152173165168192203196199211195176180191204228274324357380398438451484499513515
-9.576.8010.0010.7411.192.0113.82-4.621.8214.295.73-3.451.536.03-7.58-9.742.276.116.8111.7620.1818.2510.196.444.7410.052.977.323.102.810.39
69.1568.9367.2766.1264.9365.1065.1364.1666.0667.2666.6766.5060.7160.8060.1962.0564.2063.3365.9765.2066.2364.9662.9663.5962.8963.3264.3865.85----
657174808797991111091131281351191211271211131141261331511782042272392522822970000
121616182122242415192321262524162228364148496278929710110210510811096
12.7715.5314.5514.8815.6714.7715.7913.879.0911.3111.9810.3413.2712.5611.378.2112.5015.5618.8520.1021.0517.8819.1421.8524.2124.3723.0622.6221.6921.6421.4418.64
1420252620141519202322211921201419222530364151637282899190939288
-42.8625.004.00-23.08-30.007.1426.675.2615.00-4.35-4.55-9.5210.53-4.76-30.0035.7115.7913.6420.0020.0013.8924.3923.5314.2913.898.542.25-1.103.33-1.08-4.35
--------------------------------
--------------------------------
33.236.5194.1213.8213.8213.8235.2231232.2232.2234.6234.6263.9285.8285.6282.8276.6278.1272.5293.53298.94295.71306.07306.08316.33329.67316.63310.730000
--------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Faes Farma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Faes Farma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (k)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
26.447.556.552.138.334.627.118.726.319.818.220.81720.912.512.410.614.813.332.9166.0243.3476.4154.1893.1473.4184.147.75
16.818.919.722.226.429.632.133.327.12934.547.835.736.237.933.3-0.73738.143.0445.672.1677.0690.4898.77101.49101.17113.51
000000000000000.8542.21.94.13.223.474.094.486.346.131112.430
13.413.613.215.92021.92321.223.523.925.528.427.529.536.232.530.531.132.934.0338.2949.8759.3171.4591.59107.45115129.03
-600-1,100-1,000-1,200-5,000-4,400-6,200-40000000400300400400300300272285372330539375360518573
5678.988.48979.781.77672.876.972.778.29780.28787.783.68385.188.7113.47153.66169.83217.58222.99290.01293.71313.21290.86
121313.715.417.518.220.723.924.926.828.631.133.333.332.129.225.723.122.530.4338.4160.5667.0683.9395.25139.63205.8280.62
18.87.54.95.12.320.30.31.82.221.81.81.81.71.71.71.71.61.581.721.921.882.011.892.546.681.89
00000.91.97.59.500000000000000000012.420
13.913.411.72138.636.765.98569.9918891.495.697.797.5112.791.487.881.576.1972.8111.33111.74106.99112.88129.43126.91184.75
3.12.21.91.60000006.717.317.317.317.3017.317.317.317.3517.3553.1953.9461.552.6453.3351.7856.08
3.40.333.96.57.26.56.517.423.42937.946.855.860.86467.858.955.651.6647.2932.6719.0116.2528.8526.4721.2919.04
51.236.435.24765.866100.9125.2114143.4154.3179.5194.8205.9209.4207.6203.9188.8178.5177.21177.57259.67253.62270.68291.51351.4424.88542.37
107.2115.3123.6136145.5147.7176.9198190.9216.1232.5276.5275292.9297.1291.2286.9273.9267.2290.68331.22429.5471.2493.67581.52645.11738.09833.23
                                                       
11.99.34.166.67.388.99.911.112.614.2161819.520.520.52223.524.7925.526.1627.0127.8228.5229.7431.0831.62
42.8000000001.51.51.51.51.51.51.51.51.51.461.461.461.461.461.461.461.461.46
64.679.194.694.595.293.598.5107.1110.1120.4127.4136.8141.1145.2146.6148165.2176.7207231.28261.27295.69336.69388.96449.16512.93579.09643.38
8007007007007007007007000100-100-300-3000000-10007-40-57-92-2,489-3,062-5,285-3,081
2.61.11.11.11.11.11.11.100000000000000000000
83.993100.5102.3103.6102.6108.3117.8120131.6141.4152.2158.3164.7167.6170187.2200.1232257.54288.19323.25365.15418.23476.66541.07606.34673.38
8.714.57.310.917.214.311.514.414.61316.83225.718.919.61623.116.316.416.9819.0430.9635.6436.1941.9737.9336.5991.43
0.70.10.20.10.100.31.30000000005.55.85.677.018.0510.9211.7213.3511.971213.17
10.75.210.817.221.51421.422.72220.219.75.44.617.515.715.35.916.15.88.459.6112.669.4817.0217.1215.1317.5511.31
000001416.825.723.238.141.765.80.30.10.30.3000000004.937.4411.3212.14
00000000000035.33145.843.323.913.42.102.34.7847.717.357.326.8516.967.86
20.119.818.328.238.842.35064.159.871.378.2103.265.967.581.474.952.951.330.131.137.9556.45103.7572.2884.6979.3194.43135.9
00000000000024.842.832.131.534.721.25.91.09043.050.893.181.652.164.47.84
000000000.51.51.93.66.69.611.711.611.4000000017.3721.719.7416.92
2.92.34.752.72.618.41610.411.612.519.32110.36.25.63.13.62.74.158.399.966.414.564.944.64.821.11
2.92.34.752.72.618.41610.913.114.422.952.462.75048.749.224.88.65.248.3953.027.37.7423.9628.4628.9625.86
2322.12333.241.544.968.480.170.784.492.6126.1118.3130.2131.4123.6102.176.138.736.3446.34109.47111.0580.02108.64107.77123.39161.76
106.9115.1123.5135.5145.1147.5176.7197.9190.7216234278.3276.6294.9299293.6289.3276.2270.7293.88334.53432.72476.2498.25585.3648.84729.73835.14
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Faes Farma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Faes Farma's financial health and stability.

Assets

Faes Farma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Faes Farma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Faes Farma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Faes Farma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
2220211819212014192225303641516473838991
131415148899876558101214161919
00000000000000000330
-10-22-21-140-12-20-6-7-5-11-8-9-18-16-30-35-36-18-25
-614-65463371113179132125161614
21235222210000000000
65335431243234455978
181319133422151923313240494159677879106100
-9-28-15-14-16-11-10-8-2-4-4-10-11-16-19-21-25-59-80-102
-6-24-14-23-11-13-9-1-1-4-3-10-11-83-19-34-25-83-92-97
340-85-21610000-660-120-24-114
00000000000000000000
-214324-4134-3-18-23-26-7031-1-43-2-100
10000000000-1000-1-2000-17
-64-914-21-6-13-14-23-23-30-11-425-7-56-14-17-18-35
-2210-2-40-300-1000300-10-3
-11-12-14-10-13-15-16-7-600-4-5-6-7-10-12-13-18-14
6-6-4321-73-13-11833-1532-2338-20-3-31
8.78-15.254.81-1.7918.0911.45.1711.9221.1227.4828.1130.7737.6425.0839.8246.1852.7720.2325.84-1.22
00000000000000000000

Faes Farma stock margins

The Faes Farma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Faes Farma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Faes Farma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Faes Farma's sales revenue. A higher gross margin percentage indicates that the Faes Farma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Faes Farma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Faes Farma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Faes Farma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Faes Farma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Faes Farma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Faes Farma Margin History

Faes Farma Gross marginFaes Farma Profit marginFaes Farma EBIT marginFaes Farma Profit margin
2027e65.86 %18.74 %17.19 %
2026e65.86 %21.44 %17.96 %
2025e65.86 %21.76 %18.74 %
2024e65.86 %21.71 %18.65 %
202365.86 %22.79 %20.37 %
202264.28 %23.23 %20.41 %
202163.33 %24.37 %20.67 %
202063.08 %24.28 %19.08 %
201963.63 %22.1 %17.9 %
201862.94 %19.12 %15.91 %
201764.88 %17.87 %15.07 %
201666.13 %21.01 %16 %
201565.34 %20.28 %14.83 %
201465.73 %18.88 %13.2 %
201363.53 %15.85 %12.53 %
201264.22 %12.95 %11.07 %
201162.03 %8.33 %7.26 %
201060.26 %11.68 %9.46 %
200960.88 %12.74 %10.68 %
200860.84 %13.2 %9.95 %
200766.36 %10.5 %10.74 %
200666.65 %12.1 %11.84 %
200567.1 %11.8 %13.81 %
200466.51 %9.15 %12.48 %

Faes Farma Stock Sales Revenue, EBIT, Earnings per Share

The Faes Farma earnings per share therefore indicates how much revenue Faes Farma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Faes Farma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Faes Farma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Faes Farma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Faes Farma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Faes Farma Revenue, EBIT and net profit per share

DateFaes Farma Sales per ShareFaes Farma EBIT per shareFaes Farma Earnings per Share
2027e1.66 undefined0 undefined0.28 undefined
2026e1.65 undefined0 undefined0.3 undefined
2025e1.6 undefined0 undefined0.3 undefined
2024e1.56 undefined0 undefined0.29 undefined
20231.45 undefined0.33 undefined0.3 undefined
20221.39 undefined0.32 undefined0.28 undefined
20211.21 undefined0.29 undefined0.25 undefined
20201.2 undefined0.29 undefined0.23 undefined
20191.17 undefined0.26 undefined0.21 undefined
20181.06 undefined0.2 undefined0.17 undefined
20170.93 undefined0.17 undefined0.14 undefined
20160.76 undefined0.16 undefined0.12 undefined
20150.7 undefined0.14 undefined0.1 undefined
20140.7 undefined0.13 undefined0.09 undefined
20130.65 undefined0.1 undefined0.08 undefined
20120.64 undefined0.08 undefined0.07 undefined
20110.69 undefined0.06 undefined0.05 undefined
20100.74 undefined0.09 undefined0.07 undefined
20090.7 undefined0.09 undefined0.07 undefined
20080.75 undefined0.1 undefined0.07 undefined
20070.87 undefined0.09 undefined0.09 undefined
20060.82 undefined0.1 undefined0.1 undefined
20050.73 undefined0.09 undefined0.1 undefined
20040.71 undefined0.07 undefined0.09 undefined

Faes Farma business model

The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.com.

Faes Farma SWOT Analysis

Strengths

1. Strong brand reputation: Faes Farma SA has established itself as a reputable pharmaceutical company.

2. Diverse product portfolio: The company offers a wide range of pharmaceutical products, catering to various medical needs.

3. Technological innovation: Faes Farma SA invests in research and development to develop advanced healthcare solutions.

Weaknesses

1. Dependence on specific markets: The company's revenue heavily relies on specific geographical areas, making it vulnerable to market fluctuations.

2. Limited international presence: Faes Farma SA has a limited global reach compared to its competitors.

3. Higher production costs: The company faces challenges in maintaining cost-effectiveness due to higher production costs compared to some competitors.

Opportunities

1. Emerging markets: Faes Farma SA can expand its presence in growing markets, such as Asia and Latin America, to increase its market share.

2. Growing demand for personalized medicine: The company can capitalize on the increasing demand for customized healthcare solutions by developing personalized medicines.

3. Strategic partnerships: Faes Farma SA can form alliances with other pharmaceutical companies or healthcare providers to enhance its distribution network and access new markets.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share.

2. Stringent regulations: Compliance with stringent regulatory requirements can pose challenges for Faes Farma SA, affecting its product development timelines and profitability.

3. Economic uncertainty: Fluctuations in the global economy can impact consumer spending on healthcare products and affect the company's financial performance.

Faes Farma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Faes Farma historical P/E ratio, EBIT multiple, and P/S ratio

Faes Farma shares outstanding

The number of shares was Faes Farma in 2023 — This indicates how many shares 310.729 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Faes Farma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Faes Farma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Faes Farma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Faes Farma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Faes Farma stock splits

In Faes Farma's history, there have been no stock splits.

Faes Farma dividend history and estimates

In 2023, Faes Farma paid a dividend amounting to 0.16 EUR. Dividend means that Faes Farma distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Faes Farma provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Faes Farma’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Faes Farma's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Faes Farma Dividend History

DateFaes Farma Dividend
2027e0.17 undefined
2026e0.17 undefined
2025e0.17 undefined
2024e0.17 undefined
20230.16 undefined
20220.04 undefined
20210.2 undefined
20200.19 undefined
20190.16 undefined
20180.13 undefined
20170.11 undefined
20160.09 undefined
20150.08 undefined
20140.08 undefined
20130.05 undefined
20120.04 undefined
20110.03 undefined
20100.06 undefined
20090.05 undefined
20080.05 undefined
20070.04 undefined
20060.05 undefined
20050.04 undefined
20040.04 undefined

Faes Farma dividend payout ratio

In 2023, Faes Farma had a payout ratio of 58.66%. The payout ratio indicates the percentage of the company's profits that Faes Farma distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Faes Farma represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Faes Farma could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Faes Farma's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Faes Farma Payout Ratio History

DateFaes Farma Payout ratio
2027e46.86 %
2026e49.81 %
2025e40.45 %
2024e50.32 %
202358.66 %
202212.38 %
202179.91 %
202083.69 %
201975.02 %
201876.24 %
201776.22 %
201676.22 %
201574.24 %
201485.36 %
201360.56 %
201259.6 %
201153.1 %
201081.4 %
200973.96 %
200865.74 %
200740.73 %
200649.35 %
200543.86 %
200443.47 %
Unfortunately, there are currently no price targets and forecasts available for Faes Farma.

Faes Farma latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20120.04 0.03  (-17.61 %)2012 Q3
12/31/20110 0  (0 %)2011 Q4
12/31/20100.03 0  (-100 %)2010 Q4
6/30/20100.02 0.01  (-20.9 %)2010 Q2
12/31/20090.01 0.01  (-45.43 %)2009 Q4
12/31/20070 0.01  (78.04 %)2007 Q4
12/31/20060.04 0.01  (-72.25 %)2006 Q4
1

Eulerpool ESG Scorecard© for the Faes Farma stock

Eulerpool World ESG Rating (EESG©)

68/ 100

🌱 Environment

79

👫 Social

99

🏛️ Governance

26

Environment

Scope 1 - Direct Emissions
3,874.06
Scope 2 - Indirect emissions from purchased energy
1,652
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
5,526
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
✅
Environmentally friendly packaging
❌
Hazardous substances
✅
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees54
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Faes Farma shareholders

%
Name
Stocks
Change
Date
5.41520 % Indumenta Pueri, S.L.16,854,73604/18/2024
3.16667 % Alantra Asset Management SGIIC, S.A.9,856,236-3,077,3234/18/2024
2.83355 % The Vanguard Group, Inc.8,819,392-162,4403/31/2024
1.52181 % BlackRock Institutional Trust Company, N.A.4,736,62310,0373/31/2024
1.47235 % Dimensional Fund Advisors, L.P.4,582,65703/31/2024
1.46649 % Norges Bank Investment Management (NBIM)4,564,418-4,714,39512/31/2023
1.28125 % Fidelity Management & Research Company LLC3,987,88202/29/2024
0.80263 % Zavala Ortiz de la Torre (Iñigo)2,498,169105,14112/31/2023
0.67447 % Santander Asset Management2,099,272012/31/2023
0.67192 % Argenta Asset Management SA2,091,35206/30/2023
1
2
3
4
5
...
10

Faes Farma Executives and Management Board

Don Mariano Ucar Angulo
Faes Farma Executive Chairman of the Board (since 1991)
Compensation 1.6 M
Don Gonzalo Fernandez de Valderrama Iribarnegaray
Faes Farma Proprietary Director (since 2003)
Compensation 133,000
Don Carlos de Alcocer Torra
Faes Farma Lead Independent Director
Compensation 120,000
Dna. Belen Amatriain Corbi65
Faes Farma Independent Director
Compensation 115,000
Dna. Maria Eugenia Zugaza Salazar
Faes Farma Independent Director
Compensation 115,000
1
2
3

Most common questions regarding Faes Farma

What values and corporate philosophy does Faes Farma represent?

Faes Farma SA represents values and a corporate philosophy centered on innovation, excellence, and commitment to improving healthcare. With a focus on research and development, the company strives to develop high-quality pharmaceutical products that address unmet medical needs. With a long history dating back to 1933, Faes Farma SA emphasizes ethical business practices and sustainable growth. By leveraging its scientific expertise and state-of-the-art technologies, the company aims to provide effective therapies and contribute to the well-being of patients worldwide. Faes Farma SA's dedication to innovation and patient-centric approach makes it a reputable player in the pharmaceutical industry.

In which countries and regions is Faes Farma primarily present?

Faes Farma SA is primarily present in Spain and Portugal.

What significant milestones has the company Faes Farma achieved?

Faes Farma SA, a leading pharmaceutical company, has achieved several significant milestones throughout its history. One notable milestone is the successful development and commercialization of innovative pharmaceutical products. The company has also expanded its market reach globally, establishing a strong presence in various countries. Furthermore, Faes Farma SA has demonstrated continuous growth through strategic partnerships, collaborations, and acquisitions. These milestones reflect the company's commitment to advancing healthcare and delivering quality solutions to customers worldwide. With its relentless dedication and industry expertise, Faes Farma SA has emerged as a prominent player in the pharmaceutical sector, consistently achieving commendable results.

What is the history and background of the company Faes Farma?

Faes Farma SA is a leading pharmaceutical company with a rich history and strong background. Established in 1933, Faes Farma has grown steadily over the years to become a key player in the healthcare industry. The company specializes in the research, development, manufacturing, and commercialization of innovative drugs and health products. With a primary focus on respiratory, allergy, and anti-inflammatory treatments, Faes Farma has built a solid reputation for delivering high-quality and effective pharmaceutical solutions. Through continuous innovation and strategic partnerships, the company has successfully expanded its global presence and has become a trusted name in the pharmaceutical sector.

Who are the main competitors of Faes Farma in the market?

Some of the main competitors of Faes Farma SA in the market include pharmaceutical companies like Grupo Ferrer Internacional, Laboratorios Rubió, Almirall, and Laboratorios Normon.

In which industries is Faes Farma primarily active?

Faes Farma SA is primarily active in the pharmaceutical industry.

What is the business model of Faes Farma?

The business model of Faes Farma SA is focused on the research, development, manufacture, and commercialization of pharmaceutical products. The company specializes in the areas of prescription drugs, hospital medications, and non-prescription drugs. Faes Farma SA operates through a diversified portfolio, catering to various therapeutic areas such as respiratory, dermatology, allergy, and gastrointestinal disorders. The company aims to provide innovative and effective solutions to improve people's health and quality of life. Faes Farma SA's commitment to scientific excellence, strategic partnerships, and continuous product development enables it to meet the evolving needs of patients worldwide.

What is the P/E ratio of Faes Farma 2024?

The Faes Farma P/E ratio is 12.69.

What is the P/S ratio of Faes Farma 2024?

The Faes Farma P/S ratio is 2.37.

What is the AlleAktien quality score of Faes Farma?

The AlleAktien quality score for Faes Farma is 7/10.

What is the revenue of Faes Farma 2024?

The expected Faes Farma revenue is 484.62 M EUR.

How high is the profit of Faes Farma 2024?

The expected Faes Farma profit is 90.38 M EUR.

What is the business model of Faes Farma

Faes Farma SA is a leading pharmaceutical company specializing in the manufacturing and marketing of medicines and medical products. The company was founded in 1933 and is headquartered in Barcelona, Spain. Faes Farma operates in various business areas, including pharmaceutical products, diagnostic and laboratory services, and skincare products. Pharmaceutical products Faes Farma offers a wide range of pharmaceutical products that can be used to treat various diseases and ailments. The company focuses on the development of drugs in the areas of pain medicine, allergology, and respiratory and eye diseases. One outstanding product is Bilastine, an antihistamine used to treat allergic diseases. In 2020, the company generated sales of €136 million with Bilastine. Diagnostic and laboratory services Faes Farma also operates a division for diagnostic and laboratory services. The company offers various tests to detect and treat diseases early. For example, Faes Farma offers a test to determine if a person is suffering from celiac disease. Another example is a test that detects the presence of antibodies against SARS-CoV-2. Skincare products The company also offers a line of skincare products marketed under the brand Bionike. These products have been specifically developed for people with sensitive skin and do not contain questionable ingredients. The product range includes face creams, cleansers, and sunscreens. Faes Farma has a diversified business model based on the development of new products and the expansion into new markets. The company is focused on innovation and invests a significant portion of its sales in research and development every year. Thanks to its innovative capacity and strong market presence, Faes Farma has experienced solid growth in recent years. In 2020, the company had sales of €317.2 million. The size of the company allows for international business expansion. Faes Farma operates in over 80 countries and has a strong presence, particularly in Latin America and Asia.

What is the Faes Farma dividend?

Faes Farma pays a dividend of 0.04 EUR distributed over 2 payouts per year.

How often does Faes Farma pay dividends?

Faes Farma pays out a dividend 2 times a year.

What is the Faes Farma ISIN?

The ISIN of Faes Farma is ES0134950F36.

What is the Faes Farma WKN?

The WKN of Faes Farma is A0MKAC.

What is the Faes Farma ticker?

The ticker of Faes Farma is FAE.MC.

How much dividend does Faes Farma pay?

Over the past 12 months, Faes Farma paid a dividend of 0.16 EUR . This corresponds to a dividend yield of about 4.2 %. For the coming 12 months, Faes Farma is expected to pay a dividend of 0.17 EUR.

What is the dividend yield of Faes Farma?

The current dividend yield of Faes Farma is 4.2 %.

When does Faes Farma pay dividends?

Faes Farma pays a quarterly dividend. This is distributed in the months of February, May, February, August.

How secure is the dividend of Faes Farma?

Faes Farma paid dividends every year for the past 24 years.

What is the dividend of Faes Farma?

For the upcoming 12 months, dividends amounting to 0.17 EUR are expected. This corresponds to a dividend yield of 4.57 %.

In which sector is Faes Farma located?

Faes Farma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Faes Farma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Faes Farma from 7/8/2024 amounting to 0.116 EUR, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Faes Farma pay the last dividend?

The last dividend was paid out on 7/8/2024.

What was the dividend of Faes Farma in the year 2023?

In the year 2023, Faes Farma distributed 0.035 EUR as dividends.

In which currency does Faes Farma pay out the dividend?

The dividends of Faes Farma are distributed in EUR.

All fundamentals about Faes Farma

Our stock analysis for Faes Farma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Faes Farma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.